Allergic respiratory disease care in the COVID-19 era : A EUFOREA statement
(2020) In World Allergy Organization Journal 13(5).- Abstract
Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea, and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic... (More)
Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea, and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on AIT.
(Less)
- author
- organization
- publishing date
- 2020-05-16
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Allergen-specific immunotherapy, Allergy, Asthma, Control, COVID-19, Rhinitis, Smell and taste, Symptoms, Treatment
- in
- World Allergy Organization Journal
- volume
- 13
- issue
- 5
- article number
- 100124
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:32426089
- scopus:85085645917
- ISSN
- 1939-4551
- DOI
- 10.1016/j.waojou.2020.100124
- language
- English
- LU publication?
- yes
- id
- 2e7a81d4-b3d3-4458-9423-7a9afd24166e
- date added to LUP
- 2020-06-24 09:12:31
- date last changed
- 2024-09-19 01:05:59
@article{2e7a81d4-b3d3-4458-9423-7a9afd24166e, abstract = {{<p>Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea, and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on AIT.</p>}}, author = {{Scadding, Glenis K. and Hellings, Peter W. and Bachert, Claus and Bjermer, Leif and Diamant, Zuzana and Gevaert, Philippe and Kjeldsen, Anette and Kleine-Tebbe, Jorge and Klimek, Ludger and Muraro, Antonella and Roberts, Graham and Steinsvik, Andreas and Wagenmann, Martin and Wahn, Ulrich}}, issn = {{1939-4551}}, keywords = {{Allergen-specific immunotherapy; Allergy; Asthma; Control; COVID-19; Rhinitis; Smell and taste; Symptoms; Treatment}}, language = {{eng}}, month = {{05}}, number = {{5}}, publisher = {{BioMed Central (BMC)}}, series = {{World Allergy Organization Journal}}, title = {{Allergic respiratory disease care in the COVID-19 era : A EUFOREA statement}}, url = {{http://dx.doi.org/10.1016/j.waojou.2020.100124}}, doi = {{10.1016/j.waojou.2020.100124}}, volume = {{13}}, year = {{2020}}, }